The Role of Biologics in Chronic Rhinosinusitis With Nasal Polyps

Gayatri B. Patel; Anju T. Peters

doi:10.1177/0145561320964653

The Role of Biologics in Chronic Rhinosinusitis With Nasal Polyps

Gayatri B. Patel, Anju T. Peters^*

^*Corresponding author for this work

Medicine, Allergy Division

Research output: Contribution to journal › Editorial › peer-review

Abstract

Biologic therapy is a new treatment option for patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Currently, the only biologic with Food and Drug Administration–approval status for CRSwNP is dupilumab. Several other biologics are likely to be approved for CRSwNP, including mepolizumab and omalizumab, based on their promising phase 3 trial results. The role of biologics in the treatment paradigm requires consideration of multiple factors that have yet to be clearly established. This includes identifying patients most appropriate for biologic therapy while considering long-term safety and cost-effectiveness in the context of patient preferences and goals.

Original language	English (US)
Journal	Ear, Nose and Throat Journal
DOIs	https://doi.org/10.1177/0145561320964653
State	Accepted/In press - 2020

Keywords

benralizumab
biologics
chronic rhinosinusitis with nasal polyps (CRSwNP)
dupilumab
mepolizumab
nasal polyps
omalizumab

ASJC Scopus subject areas

Otorhinolaryngology

Access to Document

10.1177/0145561320964653

Fingerprint Dive into the research topics of 'The Role of Biologics in Chronic Rhinosinusitis With Nasal Polyps'. Together they form a unique fingerprint.

Cite this

@article{468bead106ae443d86d8f8d32fc3cbec,

title = "The Role of Biologics in Chronic Rhinosinusitis With Nasal Polyps",

abstract = "Biologic therapy is a new treatment option for patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Currently, the only biologic with Food and Drug Administration–approval status for CRSwNP is dupilumab. Several other biologics are likely to be approved for CRSwNP, including mepolizumab and omalizumab, based on their promising phase 3 trial results. The role of biologics in the treatment paradigm requires consideration of multiple factors that have yet to be clearly established. This includes identifying patients most appropriate for biologic therapy while considering long-term safety and cost-effectiveness in the context of patient preferences and goals.",

keywords = "benralizumab, biologics, chronic rhinosinusitis with nasal polyps (CRSwNP), dupilumab, mepolizumab, nasal polyps, omalizumab",

author = "Patel, {Gayatri B.} and Peters, {Anju T.}",

year = "2020",

doi = "10.1177/0145561320964653",

language = "English (US)",

journal = "Ear, Nose and Throat Journal",

issn = "0145-5613",

publisher = "Medquest Communications LLC",

}

TY - JOUR

T1 - The Role of Biologics in Chronic Rhinosinusitis With Nasal Polyps

AU - Patel, Gayatri B.

AU - Peters, Anju T.

PY - 2020

Y1 - 2020

N2 - Biologic therapy is a new treatment option for patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Currently, the only biologic with Food and Drug Administration–approval status for CRSwNP is dupilumab. Several other biologics are likely to be approved for CRSwNP, including mepolizumab and omalizumab, based on their promising phase 3 trial results. The role of biologics in the treatment paradigm requires consideration of multiple factors that have yet to be clearly established. This includes identifying patients most appropriate for biologic therapy while considering long-term safety and cost-effectiveness in the context of patient preferences and goals.

AB - Biologic therapy is a new treatment option for patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Currently, the only biologic with Food and Drug Administration–approval status for CRSwNP is dupilumab. Several other biologics are likely to be approved for CRSwNP, including mepolizumab and omalizumab, based on their promising phase 3 trial results. The role of biologics in the treatment paradigm requires consideration of multiple factors that have yet to be clearly established. This includes identifying patients most appropriate for biologic therapy while considering long-term safety and cost-effectiveness in the context of patient preferences and goals.

KW - benralizumab

KW - biologics

KW - chronic rhinosinusitis with nasal polyps (CRSwNP)

KW - dupilumab

KW - mepolizumab

KW - nasal polyps

KW - omalizumab

UR - http://www.scopus.com/inward/record.url?scp=85092283907&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85092283907&partnerID=8YFLogxK

U2 - 10.1177/0145561320964653

DO - 10.1177/0145561320964653

M3 - Editorial

C2 - 33035132

AN - SCOPUS:85092283907

JO - Ear, Nose and Throat Journal

JF - Ear, Nose and Throat Journal

SN - 0145-5613

ER -